Ca 125 is an independent prognostic marker in resected pancreatic cancer of the head of the pancreas

被引：7

作者：

Napoli, Niccolo ^{[1
]}

Kauffmann, Emanuele F. ^{[1
]}

Ginesini, Michael ^{[1
]}

Lami, Lucrezia ^{[1
]}

Lombardo, Carlo ^{[1
]}

Vistoli, Fabio ^{[1
]}

Campani, Daniela ^{[2
]}

Boggi, Ugo ^{[1
]}

机构：

[1] Univ Pisa, Div Gen & Transplant Surg, Pisa, Italy

[2] Univ Pisa, Div Pathol, Pisa, Italy

来源：

UPDATES IN SURGERY | 2023年 / 75卷 / 06期

关键词：

Pancreatic ductal adenocarcinoma; Pancreatic cancer; Survival; Prognosis; CA; 125; 19-9; SERUM-LEVELS; RECURRENCE; GUIDELINES; PATTERNS; SURVIVAL; CA-19-9; CA19-9; MUC16;

D O I：

10.1007/s13304-023-01587-4

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

The prognostic value of carbohydrate antigen 125 (Ca 125) is emerging also in pancreatic cancer (PDAC). In this study, we aim to define the prognostic value of Ca 125 in resected PDAC of the head of the pancreas. This is a single-center, retrospective study. Data from patients with a pre-operative assay of Ca 125 who underwent a pancreatic resection for PDAC between 2010 and 2018 were analyzed. As per National Comprehensive Cancer Guidelines, tumors were classified in resectable (R-PDAC), borderline resectable (BR-PDAC), and locally advanced (LA-PDAC). The Kaplan-Meier method was used to evaluate the overall survival. Cox proportional hazard regression was used to evaluate the role of pre-operative Ca 125 in predicting survival (while adjusting for confounders). The maximally selected log-rank statistic was used to identify a Ca 125 cut-off defining two groups with different survival probability. Inclusion criteria were met by 207 patients (R-PDAC: 80, BR-PDAC: 91, and LA-PDAC: 36). Ca 125 predicted overall survival before and after adjusting for confounding factors in all categories of anatomic resectability (R-PDAC: HR = 4.3; p = 0.0249) (BR-PDAC: HR = 7.82; p = 0.0024) (LA-PDAC: HR = 11.4; p = 0.0043). In BR-PDAC and LA-PDAC (n = 127), the division in two groups (high vs. low Ca 125) correlated with T stage (p = 0.0317), N stage (p = 0.0083), mean LN ratio (p = 0.0292), and tumor grading (p = 0.0143). This study confirmed the prognostic value of Ca125 in resected pancreatic cancer and, therefore, the importance of biologic over anatomic resectability. Ca 125 should be routinely assayed in surgical candidates with PDAC.

引用

页码：1481 / 1496

页数：16

共 49 条

[1] ELEVATED SERUM LEVELS OF TUMOR-MARKER CA19-9 IN ACUTE CHOLANGITIS [J].

ALBERT, MB ;

STEINBERG, WM ;

HENRY, JP .

DIGESTIVE DISEASES AND SCIENCES, 1988, 33 (10) :1223-1225

[2] Pancreatectomy with resection and reconstruction of the superior mesenteric artery [J].

Boggi, Ugo ;

Napoli, Niccolo ;

Kauffmann, Emanuele F. ;

Iacopi, Sara ;

Ginesini, Michael ;

Gianfaldoni, Cesare ;

Campani, Daniela ;

Amorese, Gabriella ;

Vistoli, Fabio .

BRITISH JOURNAL OF SURGERY, 2023, 110 (08) :901-904

[3] Prognostic implications of tumor invasion or adhesion to peripancreatic vessels in resected pancreatic cancer [J].

Boggi, Ugo ;

Del Chiaro, Marco ;

Croce, Chiara ;

Vistoli, Fabio ;

Signori, Stefano ;

Moretto, Carlo ;

Amorese, Gabriella ;

Mazzeo, Salvatore ;

Cappelli, Carla ;

Campani, Daniela ;

Mosca, Franco .

SURGERY, 2009, 146 (05) :869-881

[4] Prognostic relevance of preoperative bilirubin-adjusted serum carbohydrate antigen 19-9 in a multicenter subset analysis of 179 patients with distal cholangiocarcinoma [J].

Bolm, Louisa ;

Petrova, Ekaterina ;

Weitz, Juergen ;

Rueckert, Felix ;

Wittel, Uwe A. ;

Makowiec, Frank ;

Lapshyn, Hryhoriy ;

Bronsert, Peter ;

Rau, Bettina M. ;

Khatkov, Igor E. ;

Bausch, Dirk ;

Keck, Tobias ;

Wellner, Ulrich F. ;

Distler, Marius .

HPB, 2019, 21 (11) :1513-1519

[5] Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials) [J].

Bonnetain, Franck ;

Bonsing, Bert ;

Conroy, Thierry ;

Dousseau, Adelaide ;

Glimelius, Bengt ;

Haustermans, Karin ;

Lacaine, Francois ;

Van Laethem, Jean Luc ;

Aparicio, Thomas ;

Aust, Daniela ;

Bassi, Claudio ;

Berger, Virginie ;

Chamorey, Emmanuel ;

Chibaudel, Benoist ;

Dahan, Laeticia ;

De Gramont, Aimery ;

Delpero, Jean Robert ;

Dervenis, Christos ;

Ducreux, Michel ;

Gal, Jocelyn ;

Gerber, Erich ;

Ghaneh, Paula ;

Hammel, Pascal ;

Hendlisz, Alain ;

Jooste, Valerie ;

Labianca, Roberto ;

Latouche, Aurelien ;

Lutz, Manfred ;

Macarulla, Teresa ;

Malka, David ;

Mauer, Muriel ;

Mitry, Emmanuel ;

Neoptolemos, John ;

Pessaux, Patrick ;

Sauvanet, Alain ;

Tabernero, Josep ;

Taieb, Julien ;

van Tienhoven, Geertjan ;

Gourgou-Bourgade, Sophie ;

Bellera, Carine ;

Mathoulin-Pelissier, Simone ;

Collette, Laurence .

EUROPEAN JOURNAL OF CANCER, 2014, 50 (17) :2983-2993

[6] Mesothelin Binding to CA125/MUC16 Promotes Pancreatic Cancer Cell Motility and Invasion via MMP-7 Activation [J].

Chen, Shih-Hsun ;

Hung, Wei-Chien ;

Wang, Pu ;

Paul, Colin ;

Konstantopoulos, Konstantinos .

SCIENTIFIC REPORTS, 2013, 3

[7] 8th Edition of the AJCC Cancer Staging Manual: Pancreas and Hepatobiliary Cancers [J].

Chun, Yun Shin ;

Pawlik, Timothy M. ;

Vauthey, Jean-Nicolas .

ANNALS OF SURGICAL ONCOLOGY, 2018, 25 (04) :845-847

[8] FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer [J].

Conroy, T. ;

Hammel, P. ;

Hebbar, M. ;

Ben Abdelghani, M. ;

Wei, A. C. ;

Raoul, J. -L. ;

Chone, L. ;

Francois, E. ;

Artru, P. ;

Biagi, J. J. ;

Lecomte, T. ;

Assenat, E. ;

Faroux, R. ;

Ychou, M. ;

Volet, J. ;

Sauvanet, A. ;

Breysacher, G. ;

Di Fiore, F. ;

Cripps, C. ;

Kavan, P. ;

Texereau, P. ;

Bouhier-Leporrier, K. ;

Khemissa-Akouz, F. ;

Legoux, J. -L. ;

Juzyna, B. ;

Gourgou, S. ;

O'Callaghan, C. J. ;

Jouffroy-Zeller, C. ;

Rat, P. ;

Malka, D. ;

Castan, F. ;

Bachet, J. -B. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (25) :2395-2406

[9] A Paradigm Shifts: Neoadjuvant Therapy for Clearly Resectable Pancreatic Cancer [J].

de Geus, Susanna W. L. ;

Sachs, Teviah E. .

ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (06) :3427-3436

[10] Very high serum levels of CA 19-9 in autoimmune pancreatitis: Report of four cases and brief review of literature [J].

De Marchi, Giulia ;

Paiella, Salvatore ;

Luchini, Claudio ;

Capelli, Paola ;

Bassi, Claudio ;

Frulloni, Luca .

JOURNAL OF DIGESTIVE DISEASES, 2016, 17 (10) :697-702

← 1 2 3 4 5 →